Results 71 to 80 of about 1,025,401 (190)

Low Titers of Antidonor ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study

Transplantation Direct, 2019
Background. The ABO blood-type barrier in kidney and liver transplantation has been overcome by aggressive treatments such as B cell depletion using rituximab.
Daisuke Ueda, MD, Atsushi Yoshizawa, MD, PhD, Masakatsu Kaneshiro, MD, Yoshihiro Hirata, MD, PhD, Shintaro Yagi, MD, PhD, Koichiro Hata, MD, PhD, Hideaki Okajima, MD, PhD, Hiroto Egawa, MD, PhD, Shinji Uemoto, MD, PhD   +8 more
doaj   +1 more source

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, Volume 66, Issue 8, Page 1679-1685, August 2026.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source

Outcomes of ABO-Incompatible Kidney Transplantation in the United States [PDF]

Transplantation, 2012
ABO incompatible (ABOi) kidney transplantation is an important modality to facilitate living donor transplant for incompatible pairs. To date, reports of the outcomes from this practice in the United States have been limited to single-center studies.Using the Scientific Registry of Transplant Recipients, we identified 738 patients who underwent live ...
John R, Montgomery, Jonathan C, Berger, Daniel S, Warren, Nathan T, James, Robert A, Montgomery, Dorry L, Segev   +5 more
openaire   +2 more sources

Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption

, 2010
ABO-incompatible kidney transplantation is possible after pre-treatment with rituximab, intravenous immunoglobulin and basiliximab combined with tacrolimus, mycophenolate mofetil and prednisolone. We report on the first patient treated with this protocol
Sprogøe, Ulrik, Koefoed-Nielsen, Pernille, Just, Søren Andreas; id_orcid, Bistrup, Claus; id_orcid, Marcussen, Niels; id_orcid   +4 more
core   +1 more source

Risk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1165-1173, July 2026.
In a single‐center cohort of 577 adult LDLT recipients who underwent simultaneous splenectomy, clinically significant SFSS grade B/C (ILTS‐iLDLT‐LTSI 2023) occurred in 18.2% and was associated with inferior graft survival. Multivariate analysis identified MELD ≥ 30, NLR ≥ 4.5, and donor age ≥ 50 years as independent risk factors, which risk rising ...
Kyohei Yugawa, Takeo Toshima, Shinji Itoh, Takashi Motomura, Shohei Yoshiya, Norifumi Iseda, Tomoharu Yoshizumi   +6 more
wiley   +1 more source

Desensitization With Antigen-Specific Immunoadsorption Interferes With Complement in ABO-Incompatible Kidney Transplantation

, 2012
Background. Complement activation was characterized during and after desensitization treatment in 19 consecutive patients receiving ABO-incompatible (ABOi) living donor kidney transplants to assess the effect of desensitization protocol including antigen-
Nilsson Ekdahl, Kristina,, Wadström, Jonas,, Larsson, Erik,, Gunnar Tufveson, Bo Nilsson, Nilsson, Bo,, Tufveson, Gunnar,, Nilsson, Tomas, Thomas Nilsson, Larsson, Erik, Tufveson, Gunnar, Biglarnia, Ali-Reza,, Jonas Wadström, Biglarnia, Ali Reza, Nilsson, Thomas,, Wadström, Jonas, Ali-Reza Biglarnia, Nilsson, Bo, Kristina Nilsson Ekdahl, Erik Larsson   +19 more
core   +1 more source

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1356-1364, July 2026.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata, Tetsuya Tajima, Satoshi Ogiso, Shinji Uemoto, Etsuro Hatano   +4 more
wiley   +1 more source

Feasibility and outcomes of kidney transplantation in patients with end‐stage kidney disease after haemopoietic stem cell transplantation

Internal Medicine Journal, Volume 56, Issue 7, Page 1174-1181, July 2026.
Abstract Background Advances in haemopoietic stem cell transplantation (HSCT) have improved long‐term survival, but they have also led to late complications, such as nephropathy. However, the safety and feasibility of kidney transplantation (KT) in patients with HSCT‐related end‐stage kidney disease (ESKD) remain unclear.
Bioh Kim, Seunghyeok Choi, Hanbi Lee, Hye‐Eun Yoon, Hohyung Nam, Silvia Park, Byung Ha Chung   +6 more
wiley   +1 more source

Clinical Utility of Ultrasound in Detecting Subcapsular Hematoma after ABO Incompatible Kidney Transplantation

Journal of Surgical Ultrasound
A subcapsular hematoma after kidney transplantation is a rare but potentially graft-threatening complication that can result in the Page kidney phenomenon. Early diagnosis and timely management are critical to preserve the graft function.
Hee Chul Yu, Hong Pil Hwang
doaj   +1 more source

Pilot Experience with ABO-Incompatible Kidney Transplantation as a Second Transplant. [PDF]

Urol Int, 2019
<b><i>Background:</i></b> Despite advances in immunosuppressant medications, improvement in long-term survival for kidney transplant recipients has been more difficult to achieve. In fact, the number of patients with failing grafts who must either return to dialysis or undergo a second transplant is increasing.
Uchida J, Kosoku A, Kabei K, Nishide S, Shimada H, Iwai T, Kuwabara N, Naganuma T, Maeda K, Yoshikawa Y, Kumada N, Takemoto Y, Nakatani T.   +12 more
europepmc   +3 more sources